2019
Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent
Saito Y, Baumbach A, Wijns W, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent. Catheterization And Cardiovascular Interventions 2019, 96: 1023-1028. PMID: 31769161, DOI: 10.1002/ccd.28609.Peer-Reviewed Original ResearchConceptsHigh-risk patientsClinical outcomesComer studyI trialDurable polymer everolimus-eluting stentsTarget vessel myocardial infarctionSirolimus-eluting coronary stentYear clinical outcomesTarget lesion failureVessel myocardial infarctionLow-risk patientsWorse clinical outcomesEverolimus-eluting stentsHigh-risk groupLow-risk groupStrict eligibility criteriaFIREHAWK stentLesion failurePrimary endpointRandomized trialsMyocardial infarctionRisk groupsInclusion criteriaComplex lesionsXIENCE stent
2014
TCT-597 Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials
Ormiston J, Lansky A, Donohoe D, Knape C, Vrolix M, Verheye S, Schoors D, Wijns W. TCT-597 Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials. Journal Of The American College Of Cardiology 2014, 64: b174. DOI: 10.1016/j.jacc.2014.07.661.Peer-Reviewed Original Research
2010
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6: 437-46. PMID: 20884430, DOI: 10.4244/eij30v6i4a75.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsClinical outcomesStent typeMajor adverse cardiac eventsTwo-year event ratesSPIRIT IIIPaclitaxel-eluting coronary stentsSPIRIT III trialYear clinical outcomesAdverse cardiac eventsCardiac eventsIII trialsPE groupTwo-vesselPatientsEvent ratesCoronary stentsTrialsVessel treatmentStentsOutcomesVesselsSignificant interactionStentingLesionsLONG TERM RESULTS FOR THE DIVERGE TRIAL: 1 AND 2 YEAR CLINICAL OUTCOMES FOR THE AXXESS BIOLIUMS A9 ELUTING SELF EXPANDING STENT FOR THE TREATMENT OF DE NOVO BIFURCATION LESIONS
Lansky A, Verheye S, Ormiston J, Dubois C, Cristea E, Mehran R, Trauthen B, Johnson R. LONG TERM RESULTS FOR THE DIVERGE TRIAL: 1 AND 2 YEAR CLINICAL OUTCOMES FOR THE AXXESS BIOLIUMS A9 ELUTING SELF EXPANDING STENT FOR THE TREATMENT OF DE NOVO BIFURCATION LESIONS. Journal Of The American College Of Cardiology 2010, 55: a199.e1870. DOI: 10.1016/s0735-1097(10)61871-2.Peer-Reviewed Original Research
2005
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction
Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. European Heart Journal 2005, 26: 667-674. PMID: 15734768, DOI: 10.1093/eurheartj/ehi167.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIPercutaneous coronary interventionST-segment recoveryMyocardial blushCoronary interventionMultivariable analysisPrognostic utilityMyocardial infarctionGreater prognostic utilityStrongest prognostic variableYear clinical outcomesIncremental prognostic informationCADILLAC trialReperfusion therapyReperfusion successClinical outcomesGrade 2/3Independent correlatesMicrocirculatory integrityPrognostic informationUnivariate analysisPoor survivalCumulative rate